MAPT and Alzheimer disease: This framework proposes to define AD based on amyloid abnormalities (‘A’), tau protein changes (‘T’), and evidence of neurodegeneration (‘N’), irrespective of clinical phenotypes and even in the absence of cognitive symptoms.